1. MAD2γ, a novel MAD2 isoform, reduces mitotic arrest and is associated with resistance in testicular germ cell tumors
   Alejandro López-Saavedra et al, 2016, Cell Cycle CrossRef
2. Single-cell sequencing reveals MYC targeting gene MAD2L1 is associated with prostate cancer bone metastasis tumor dormancy
   Xing Wang et al, 2022, BMC Urology CrossRef
3. Expression of epidermal growth factor-like domain 7 may be a predictive marker of the effect of neoadjuvant chemotherapy for locally advanced uterine cervical cancer
   Makoto Yamauchi et al, 2016, Oncology Letters CrossRef
4. Sirtuin1 expression predicts the efficacy of neoadjuvant chemotherapy for locally advanced uterine cervical cancer
   MASATOMO TERAMAE et al, 2015, Molecular and Clinical Oncology CrossRef
5. Structure–Biological Function Relationship Extended to Mitotic Arrest-Deficient 2-Like Protein Mad2 Native and Mutants-New Opportunity for Genetic Disorder Control
   Speranta Avram et al, 2014, International Journal of Molecular Sciences CrossRef
6. MAD2 in the Spotlight as a Cancer Therapy Regulator
   null null et al, 2016, International Journal of Cancer and Oncology CrossRef
7. BUB1 Immunolocalization in Breast Carcinoma: Its Nuclear Localization as a Potent Prognostic Factor of the Patients
   Kiyoshi Takagi et al, 2013, Hormones and Cancer CrossRef
8. Expression of the mitotic-arrest deficiency 2 is associated with chemotherapy resistance in ovarian serous adenocarcinoma
   YUSUKE NAKANO et al, 2012, Oncology Reports CrossRef
9. MAD2 Expression in Ovarian Carcinoma: Different Expression Patterns and Levels among Various Types of Ovarian Carcinoma and Its Prognostic Significance in High-Grade Serous Carcinoma
   Po Eun Park et al, 2013, Korean Journal of Pathology CrossRef